ViiV close to licensing out Celsentri in India; rules out compulsory licensing concerns
This article was originally published in Scrip
Executive Summary
ViiV Healthcare, the new holder of rights to Celsentri (maraviroc), is in advanced discussions to potentially license out the HIV therapy in India, a move that could perhaps work in its favour against any potential compulsory licensing challenge.